

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSING AGREEMENT WITH KIOMED

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on September 26, 2022, Hansoh (Shanghai) Healthtech Company Limited* (翰森(上海)健康科技有限公司), Jiangsu Hansoh Pharmaceutical Group Company Limited* (江蘇豪森藥業集團有限公司) and Jiangsu Hengte Pharmaceutical Sales Company Limited* (江蘇恒特醫藥銷售有限公司) (collectively, the “**Licensees**”), all wholly-owned subsidiaries of the Company, entered into an exclusive license agreement (the “**Licensing Agreement**”) with KiOmed Pharma SA (“**KiOmed**”).

Pursuant to the Licensing Agreement, the Licensees obtained an exclusive license from KiOmed to develop and commercialize KiOmedine^{vs}One for the treatment of osteoarthritis within China’s mainland, Macau and Taiwan (the “**Territory**”). The Licensees will be responsible for the development, regulatory approval and commercialization of KiOmedine^{vs}One and its future extensions in the Territory, and will pay an upfront payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to EUR66 million, plus double digit tiered royalties on future net product sales.

ABOUT KIOMEDINE^{vs}ONE

KiOmedine^{vs}One is a new generation single injection for the treatment of knee osteoarthritis based on world-first exclusive animal free KiOmedine[®] CM-Chitosan. KiOmedine[®] CM-Chitosan is a highly purified polysaccharide derived from Agaricus Bisporus (button mushroom) and a patented technology made in Belgium. Different from hyaluronic acid, KiOmedine^{vs}One has dual mechanism of action to tackle osteoarthritis discomfort and other symptoms by reducing oxidative stress and enhancing joint lubrication. Clinical studies have shown that after a single injection of KiOmedine^{vs}One, significant pain reduction was observed within 2 weeks and the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score was reduced by 66%, with a long-lasting osteoarthritis symptom reduction for at least 6 months. KiOmedine^{vs}One has been granted the CE mark and launched in Europe in 2021.

ABOUT KIOMED

Based in Belgium, KiOmed has a history of innovation and expertise in exclusive natural chitosan chemistry. KiOmed develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as osteoarthritis, skin aging and ophthalmology. To the best knowledge and belief of the Company, KiOmed is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 26, 2022

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*